Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Authors
Keywords
Multiple sclerosis, Clinically isolated syndrome, Disease activity, Neurofilament light chain, CHI3L1, CXCL10, Brain volume
Journal
Journal of Neuroinflammation
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-19
DOI
10.1186/s12974-018-1249-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
- (2018) Christian Barro et al. BRAIN
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Multiple sclerosis biomarkers: Helping the diagnosis?
- (2018) E. Thouvenot REVUE NEUROLOGIQUE
- Biomarkers in Multiple Sclerosis
- (2018) Anu Paul et al. Cold Spring Harbor Perspectives in Medicine
- Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
- (2017) I. Håkansson et al. EUROPEAN JOURNAL OF NEUROLOGY
- CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis
- (2017) Piotr Iwanowski et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Brain Atrophy in Multiple Sclerosis
- (2017) Jaume Sastre-Garriga et al. NEUROIMAGING CLINICS OF NORTH AMERICA
- Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
- (2017) Lenka Novakova et al. NEUROLOGY
- From neurofilament research to multiple sclerosis clinical practice
- (2017) Benedetta Bodini et al. NEUROLOGY
- Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
- (2016) Jens Kuhle et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Brain MRI atrophy quantification in MS
- (2016) Maria A. Rocca et al. NEUROLOGY
- Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
- (2016) Jonathan D. Rohrer et al. NEUROLOGY
- Neurofilament light chain level is a weak risk factor for the development of MS
- (2016) Georgina Arrambide et al. NEUROLOGY
- Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis
- (2016) Sandra Hellberg et al. Cell Reports
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
- (2015) J. Kuhle et al. NEUROLOGY
- Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
- (2015) M Alba Mañé Martínez et al. Multiple Sclerosis Journal
- Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
- (2015) G Hinsinger et al. Multiple Sclerosis Journal
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- (2013) Veronica Popescu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis (P03.055)
- (2012) M. Vagberg et al. NEUROLOGY
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Neurofilament light as a prognostic marker in multiple sclerosis
- (2010) Jonatan Salzer et al. Multiple Sclerosis Journal
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
- (2010) N. De Stefano et al. NEUROLOGY
- Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
- (2009) F. Sellebjerg et al. NEUROLOGY
- Rapid magnetic resonance quantification on the brain: Optimization for clinical usage
- (2008) J.B.M. Warntjes et al. MAGNETIC RESONANCE IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started